BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be we ...

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZ ...

The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities BOSTON and ROLLE, Switzerland, Jan. 25, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETI ...

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel BOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its  Precision Biology Services portfolio. RareCyte is an innovative precision bi ...

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA ...

Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today BOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA ...

Insights from multimodal datasets on the platform fuel cancer research in Canada BOSTON and ROLLE, Switzerland, Jan. 8, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering. Exactis Innovation is a non-profit network of hospit ...

The Hospital will use SOPHiA GENETICS technology to streamline workflows and expedite research BOSTON and ROLLE, Switzerland, Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2023 Results Conference Call November 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Yuko Oku - Morgan Stanley Kyle Boucher - TD Cowen Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS Third Quarter ...

Exhibit 99.1 Table of Contents SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements F-2 Table of Contents SOPHiA GENETICS SA, Rolle Interim Condensed Consolidated Statements of Loss (Amounts in USD thousands, except per share data) (Unaudited) | | | | | Three months ended | | | | Nine months ended | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | September 30, | | | | September 30, | | | | Notes | | 2023 | | 2022 | | 2023 | | 2022 | | Revenue | 5 | $ | 1 ...